Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FAB-HCC Pilot Study
2024-516835-29-00Phase 2Completed
- Sponsor
- Medical University of Vienna
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab, bevacizumab and fecal microbiome transplant in hepatocellular carcinoma (HCC), sponsored by Medical University of Vienna. Primary endpoint: Treatment-related adverse events (incidence and severity). Started Dec 2024; status: completed.
02
Drugs
atezolizumabbevacizumabfecal microbiome transplant
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2024-516835-29-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516835-29-00.